Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Martina Emde"'
Autor:
Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundImmunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (comb
Externí odkaz:
https://doaj.org/article/c65a30545a9545fdbf7aa6e375ae1aa6
Autor:
Dirk Hose, Susanne Beck, Hans Salwender, Martina Emde, Uta Bertsch, Christina Kunz, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Jérôme Moreaux, Anja Seckinger
Publikováno v:
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-12 (2019)
Abstract Background Personalized and risk-adapted treatment strategies in multiple myeloma prerequisite feasibility of prospective assessment, reporting of targets, and prediction of survival probability in clinical routine. Our aim was first to set
Externí odkaz:
https://doaj.org/article/d628a9791f6948da82e13c934ac32d97
Autor:
Anja Seckinger, Jens Hillengass, Martina Emde, Susanne Beck, Christoph Kimmich, Tobias Dittrich, Michael Hundemer, Anna Jauch, Ute Hegenbart, Marc-Steffen Raab, Anthony D. Ho, Stefan Schönland, Dirk Hose
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in comb
Externí odkaz:
https://doaj.org/article/10b1a8a6494740e09f9f6bf2be1200c3
Autor:
Katja Weisel, Dirk Hose, Jérôme Moreaux, Hartmut Goldschmidt, Hans Salwender, Christoph Scheid, Anna Jauch, Martina Emde, Mathias Hänel, Anja Seckinger, Susanne Beck, Christina Kunz, Uta Bertsch, Marc S. Raab, Thomas Hielscher
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, 2019, 12 (1), ⟨10.1186/s13045-019-0750-5⟩
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-12 (2019)
Journal of Hematology & Oncology, 2019, 12 (1), ⟨10.1186/s13045-019-0750-5⟩
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-12 (2019)
Background Personalized and risk-adapted treatment strategies in multiple myeloma prerequisite feasibility of prospective assessment, reporting of targets, and prediction of survival probability in clinical routine. Our aim was first to set up and pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d34cb9fa986bc1a3bb83183201873b
https://biblio.vub.ac.be/vubir/prospective-target-assessment-and-multimodal-prediction-of-survival-for-personalized-and-riskadapted-treatment-strategies-in-multiple-myeloma-in-the-gmmgmm5-multicenter-trial(83daf01f-93a2-4146-9187-0b3a5583bc5c).html
https://biblio.vub.ac.be/vubir/prospective-target-assessment-and-multimodal-prediction-of-survival-for-personalized-and-riskadapted-treatment-strategies-in-multiple-myeloma-in-the-gmmgmm5-multicenter-trial(83daf01f-93a2-4146-9187-0b3a5583bc5c).html
Autor:
Hans Salwender, Jan Dürig, Susanne Lipp, Katja Weisel, Mathias Hänel, Michael Schmitt, Hartmut Goldschmidt, Anthony D. Ho, Angela Hückelhoven, Martina Emde, Anita Schmitt, Anja Seckinger, Uta Bertsch, Igor Wolfgang Blau, Michael Hundemer, Dirk Hose
Publikováno v:
Oncotarget
// Michael Schmitt 1, * , Angela G. Huckelhoven 1, * , Michael Hundemer 1 , Anita Schmitt 1 , Susanne Lipp 1 , Martina Emde 1 , Hans Salwender 2 , Mathias Hanel 3 , Katja Weisel 4 , Uta Bertsch 1 , Jan Durig 5 , Anthony D. Ho 1 , Igor Wolfgang Blau 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c3792cab2fca34ded7949c5c13c3b66
http://europepmc.org/articles/PMC5689578
http://europepmc.org/articles/PMC5689578
Autor:
Marc S. Raab, Hans Salwender, Hartmut Goldschmidt, Katja Weisel, Pieter Sonneveld, Uta Bertsch, Thomas Hielscher, Dirk Hose, Anna Jauch, Ingo G.H. Schmidt-Wolf, Mathias Haenel, Carsten Müller-Tidow, Christof Scheid, Hans Martin, Kai Neben, Henk M. Lokhorst, Manuela Hummel, Jens Hillengass, Anja Seckinger, Wolfgang Knauf, Igor Wolfgang Blau, Ulrich Duehrsen, Bronno van der Holt, Martina Emde, Susanne Beck, Bernd Lathan, Hans-Walter Lindemann, Jan Dürig
Introduction The inclusion of "novel" agents including proteasome inhibitors or IMiD-derivatives in the treatment of multiple myeloma significantly improves patient survival. Results of several study groups suggest incorporating at least one "novel a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9653d4b89f97ebceed46791b8ac4a4a6
Autor:
Ramona Murr, Elisabetta Ada Cavalcanti-Adam, Juana Merino, Reto Gianotti, Aintzane Zabaleta, Marina Bacac, Anthony D. Ho, Martina Emde, Jose Antonio Delgado, Samuel Moser, Felipe Prosper, Lydia Jasmin Harnisch, Anna Luise Grab, Jens Hillengass, Melanie Latzko, Klaus Strein, Ralf Hosse, Tanja Fauti, Jesús F. San Miguel, Remo Lüoend, Brigitte Neuber, Bruno Paiva, Pablo Umana, Minh Diem Vu, Christian Klein, Camille Delon, Anja Seckinger, Susanne Lipp, Michael Hundemer, Laura Moreno, Dirk Hose
Publikováno v:
Cancer Cell
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+ T cell/myelom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3e8fb7b6e31ecaf1ebc31b68dfbe19
https://biblio.vub.ac.be/vubir/target-expression-generation-preclinical-activity-and-pharmacokinetics-of-the-bcmat-cell-bispecific-antibody-em801-for-multiple-myeloma-treatment(3de0c7eb-7a6c-49c6-ab48-956cf6c1a52a).html
https://biblio.vub.ac.be/vubir/target-expression-generation-preclinical-activity-and-pharmacokinetics-of-the-bcmat-cell-bispecific-antibody-em801-for-multiple-myeloma-treatment(3de0c7eb-7a6c-49c6-ab48-956cf6c1a52a).html
Autor:
Hartmut Goldschmidt, Anja Seckinger, Michael Heider, Ruth Eichner, Katja Weisel, Hans Salwender, Florian Bassermann, Uta Bertsch, Martina Emde, Dirk Hose, Christof Scheid, Jacob Stroh
Publikováno v:
Blood. 134:3187-3187
Introduction: Lenalidomide-based maintenance therapy is the currently approved standard of care for multiple myeloma (MM) patients after high-dose melphalan and autologous stem cell transplantation (HD-Mel), which significantly prolongs progression-f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35ea62c7c3f2effe70cb55a6c1c44ab4
https://doi.org/10.1182/blood-2019-130734
https://doi.org/10.1182/blood-2019-130734
Publikováno v:
Blood. 134:3078-3078
Background. Survival in AL-amyloidosis is thought to be primarily determined by signs and symptoms caused by deposition of amyloid light chains, most prominently in the heart. In contrast, molecular characteristics of the underlying malignant plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b8d684097e8afd5b0dec8ad018d1e1c
https://doi.org/10.1182/blood-2019-131161
https://doi.org/10.1182/blood-2019-131161
Publikováno v:
Blood. 134:1801-1801
Aim of our study is to implement RNA-sequencing as basis for risk adapted and targeted treatment-strategies in multiple myeloma. We establish assessment of malignant plasma cell proliferation and risk-stratification de novo (HDHRS) by RNA-sequencing,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ee5c4bd9f292dc8d969c6e8bb2e64d4
https://doi.org/10.1182/blood-2019-131159
https://doi.org/10.1182/blood-2019-131159